Celcuity (NASDAQ:CELC) Given New $150.00 Price Target at Stifel Nicolaus

Key Points

• Stifel Nicolaus lowered Celcuity’s price target to $150 from $175 while maintaining a “buy” rating, implying 73.21% upside from the previous close.
• Analyst sentiment remains broadly positive: 10 analysts rate the stock a Buy and one rates it Sell, producing a consensus “Moderate Buy” rating and a $153.64 average target.
• Celcuity shares fell 6.0% to open at $86.60 after the company reported a quarterly EPS loss of $1.44, missing estimates, while revenue of $0.09 million came in well below the $4.42 million consensus.

Celcuity (NASDAQ:CELC - Get Free Report) had its target price decreased by equities researchers at Stifel Nicolaus from $175.00 to $150.00 in a report released on Friday,Benzinga reports. The firm currently has a "buy" rating on the stock. Stifel Nicolaus' price objective indicates a potential upside of 73.21% from the stock's previous close.

A number of other research analysts also recently issued reports on CELC. Needham & Company LLC dropped their price target on shares of Celcuity from $157.00 to $140.00 and set a "buy" rating on the stock in a research report on Friday. Wells Fargo & Company lowered their target price on shares of Celcuity from $183.00 to $166.00 and set an "overweight" rating for the company in a research note on Wednesday, June 3rd. Leerink Partners set a $155.00 price target on shares of Celcuity in a research report on Tuesday, June 2nd. Weiss Ratings upgraded Celcuity from a "sell (e+)" rating to a "sell (d-)" rating in a report on Thursday, June 4th. Finally, Macquarie Infrastructure set a $160.00 price objective on Celcuity in a research report on Thursday, May 28th. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $153.64.

Celcuity Trading Down 6.0%

Shares of CELC stock opened at $86.60 on Friday. The stock has a market cap of $4.22 billion, a price-to-earnings ratio of -22.21 and a beta of 0.20. The stock has a 50-day moving average of $93.81 and a 200-day moving average of $108.56. The company has a current ratio of 12.31, a quick ratio of 12.31 and a debt-to-equity ratio of 6.04. Celcuity has a 1-year low of $44.42 and a 1-year high of $151.02.

Celcuity (NASDAQ:CELC - Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($1.44) EPS for the quarter, missing analysts' consensus estimates of ($1.16) by ($0.28). The company had revenue of $0.09 million during the quarter, compared to the consensus estimate of $4.42 million. On average, equities research analysts forecast that Celcuity will post -3.76 earnings per share for the current year.

Institutional Investors Weigh In On Celcuity

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Brandywine Managers LLC acquired a new position in shares of Celcuity during the second quarter valued at about $693,000. Nan Fung Group Holdings Ltd bought a new stake in Celcuity in the 2nd quarter valued at about $2,960,746,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in Celcuity in the 2nd quarter valued at about $9,567,000. Elevation Point Wealth Partners LLC acquired a new position in Celcuity during the 2nd quarter worth approximately $216,000. Finally, Blue Owl Capital Holdings LP bought a new position in Celcuity in the second quarter worth approximately $131,000. 63.33% of the stock is owned by institutional investors.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source